Results 291 to 300 of about 76,191 (305)
Some of the next articles are maybe not open access.
The Indian Journal of Pediatrics, 2005
Transfusion-associated graft-versus-host disease (TA-GVHD) is an under-diagnosed condition in clinical practice. It can occur in immunocompromised as well as immunocompetent hosts and may follow allogeneic bone marrow transplant or transfusion from a related donor. The clinical course is stormy with a high mortality rate.
Inderpreet Sohi, Sunitha Jacob
openaire +3 more sources
Transfusion-associated graft-versus-host disease (TA-GVHD) is an under-diagnosed condition in clinical practice. It can occur in immunocompromised as well as immunocompetent hosts and may follow allogeneic bone marrow transplant or transfusion from a related donor. The clinical course is stormy with a high mortality rate.
Inderpreet Sohi, Sunitha Jacob
openaire +3 more sources
New England Journal of Medicine, 1988
Graft-versus-host disease (GVHD) holds a dual place in contemporary medicine. Clinically, it presents a serious problem in histocompatible bone marrow transplantation, and it is the principal limit...
openaire +3 more sources
Graft-versus-host disease (GVHD) holds a dual place in contemporary medicine. Clinically, it presents a serious problem in histocompatible bone marrow transplantation, and it is the principal limit...
openaire +3 more sources
Targeting neovascularization in GVHD
Blood, 2013In this issue of Blood, Leonhardt et al report that neovascularization during graft-versus-host disease (GVHD) is regulated by av integrins and the micro RNA miR-100.
openaire +3 more sources
2002
The essential requirements for the induction of GvHD have been known since Billingham [35], in 1966, defined what is necessary: “1. The graft must contain immunologically competent cells. 2. The host must possess important transplantation isoantigens that are lacking in the graft donor, so that the host appears foreign to it and is ...
openaire +2 more sources
The essential requirements for the induction of GvHD have been known since Billingham [35], in 1966, defined what is necessary: “1. The graft must contain immunologically competent cells. 2. The host must possess important transplantation isoantigens that are lacking in the graft donor, so that the host appears foreign to it and is ...
openaire +2 more sources
2002
Allogeneic hematopoietic stem cell transplantation (HSCT), today, is the treatment of choice for life-threatening diseases such as aplastic anemia (AA), severe combined immunodeficiency (SCID), leukemia, and many other diseases [69]. The spectrum of indications for allogeneic HSCTs has steadily increased in recent years. At present approximately 20,000
openaire +2 more sources
Allogeneic hematopoietic stem cell transplantation (HSCT), today, is the treatment of choice for life-threatening diseases such as aplastic anemia (AA), severe combined immunodeficiency (SCID), leukemia, and many other diseases [69]. The spectrum of indications for allogeneic HSCTs has steadily increased in recent years. At present approximately 20,000
openaire +2 more sources
2019
There are numerous causes of acute and chronic kidney disease following HSCT. Excluding nephrotoxic drugs and infections, the role of GVHD in the genesis of several glomerulopathies is a controversial or incompletely understood subject. Transplant-associated thrombotic microangiopathy (TA-TMA) has been associated with exposure to calcineurin inhibitors
Sangeeta Hingorani +6 more
openaire +2 more sources
There are numerous causes of acute and chronic kidney disease following HSCT. Excluding nephrotoxic drugs and infections, the role of GVHD in the genesis of several glomerulopathies is a controversial or incompletely understood subject. Transplant-associated thrombotic microangiopathy (TA-TMA) has been associated with exposure to calcineurin inhibitors
Sangeeta Hingorani +6 more
openaire +2 more sources
2005
Transfusion-associated graft versus host disease (TA-GvHD), an often fatal immunological complication of blood transfusion, was first reported in the 1960’s in individuals with haematological malignancies and infants with congenital immunodeficiencies. In infants, the clinical stigmata was called runting disease [1].
openaire +2 more sources
Transfusion-associated graft versus host disease (TA-GvHD), an often fatal immunological complication of blood transfusion, was first reported in the 1960’s in individuals with haematological malignancies and infants with congenital immunodeficiencies. In infants, the clinical stigmata was called runting disease [1].
openaire +2 more sources
The International Journal of Cell Cloning, 1986